Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.

Pharmacogenomics - 1 Feb 2024

Pepe Francesco, Venetis Konstantinos, Cursano Giulia, Frascarelli Chiara, Pisapia Pasquale, Vacirca Davide, Scimone Claudia, Rappa Alessandra, Russo Gianluca, Mane Eltjona, Pagni Fabio, Castellano Isabella, Troncone Giancarlo, Angelis Carmine De, Curigliano Giuseppe, Guerini-Rocco Elena, Malapelle Umberto, Fusco Nicola

Abstract excerpt

Introduction: PIK3CA gene mutations occur in approximately 40% of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancers (MBCs), electing them to targeted therapy. Testing PIK3CA status is complex due to selection of biological specimen and testing method. Materials & methods: This work investigates real-life experience on PIK3CA testing in HR+/HER2- MBC. Clinical, technical and molecular...

Topics

Join the communities discussing this publication.

Breast Neoplasms
Class I Phosphatidylinositol 3-Kinases
Erb-b2 Receptor Tyrosine Kinases
PIK3CA gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pathology, Molecular

Source

Identifiers

PMID: 38440825
DOI: 10.2217/pgs-2023-0238

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.PMID 38440825Read ↗

PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.Semantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast CancerSemantic proximity Read ↗

Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue.Semantic proximity Read ↗

Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights.Semantic proximity Read ↗

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.Semantic proximity Read ↗

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.Semantic proximity Read ↗

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer.Semantic proximity Read ↗

PIK3CA Mutational Profiling in a Patient Cohort with HR+/HER2- Advanced Metastatic Breast Cancer at a Tertiary Cancer CenterSemantic proximity Read ↗

PIK3CA mutations in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.